APOKYN NEWS HIGHLIGHTS Media Articles Related to Apokyn (Apomorphine)
Parkinson's Disease Alters Patient's Ability To Learn From Rewards While Treatment Affects Ability To Learn From Negative Outcomes
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2009.07.02]
A new neuropsychological memory test is helping to uncover how Parkinson's disease can alter people's ability to learn about the consequences of the choices they make. The test was developed by Dr. Mark Gluck, professor of neuroscience at the Center for Molecular and Behavioral Neuroscience at Rutgers University, Newark, working with co-researchers at Rutgers, New York University, and in Hungary.
Neupro(R) (rotigotine Transdermal Patch) Can Now Be Prescribed To All Patients With Idiopathic Parkinson's Disease In Europe
Source: Pain / Anesthetics News From Medical News Today [2009.06.30]
UCB announced that Neupro(R) (rotigotine transdermal patch) can now be prescribed to all patients with idiopathic Parkinson's disease in Europe and is newly available for the symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome (RLS) in adults. This follows the decision of the European Commission to lift treatment restrictions on Neupro® in line with the recommendation of the European Medicines Agency (EMEA), issued on 29 May 2009.
Announcing National MS And Parkinson's Disease Registries Act
Source: Multiple Sclerosis News From Medical News Today [2009.06.19]
Senator Byron Dorgan (ND) on Tuesday introduced legislation that would for the first time establish a national coordinated system to collect and analyze data on multiple sclerosis and Parkinson's disease. Accurate incidence and prevalence information on these two diseases currently does not exist. Click here to ask your Senator to support this legislation.
All Party Parliamentary Group For Parkinson's Disease Announces Report & Parkinson's Disease Society Launches Fair Care For Parkinson's
Source: Conferences News From Medical News Today [2009.06.17]
When: 8 July 2009 6:00pm - 8:00pm What: Launch of the APPG's report into inequalities of access to services for people with Parkinson's and their carers. In response to the report, the Parkinson's Disease Society will also launch Fair Care for Parkinson's, calling for the Government to ensure the APPG report recommendations are carried out.
Parkinson's Disease
Source: MedicineNet Amyotrophic Lateral Sclerosis Specialty [2009.04.28]
Title: Parkinson's Disease
Category: Diseases and Conditions
Created: 12/31/1997
Last Editorial Review: 4/28/2009
Published Studies Related to Apokyn (Apomorphine)
Apomorphine nodules in Parkinson's disease: best practice considerations. [2008.10]
Apomorphine [generic for Apokyn] hydrochloride infusion therapy is used by approximately 1000 people with advanced Parkinson's disease in the UK (Britannia Pharmaceuticals Ltd, 2008).
Comparative cross-over study of sildenafil and apomorphine for treating erectile dysfunction. [2008.09]
OBJECTIVE: To compare the effectiveness, safety and tolerability of sildenafil and apomorphine [generic for Apokyn] in Brazilian patients with erectile dysfunction (ED) of various causes... CONCLUSIONS: Sildenafil is more effective than apomorphine for treating ED, in the domains of erectile function, satisfaction with sexual intercourse and overall satisfaction, and was the drug preferred by most of the patients.
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008.03]
Many patients with advanced Parkinson's disease (PD) experience motor complications, which negatively impact quality of life, despite optimized oral therapy.
Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study. [2008.02]
OBJECTIVE: To determine whether low concentrations of a dopamine agonist worsen parkinsonism, which would suggest that activation of presynaptic dopamine autoreceptors causes a super-off state... CONCLUSIONS: Subthreshold concentrations of apomorphine [generic for Apokyn] did not worsen parkinsonism, suggesting that presynaptic dopamine autoreceptors are not important to the motor response in moderate to advanced Parkinson disease. Trial Registration clinicaltrials.gov Identifier: NCT00472355.
Apomorphine for the acute treatment of "off" episodes in Parkinson's disease. [2008]
Many patients with advanced Parkinson's disease (PD) experience motor complications, which negatively impact quality of life, despite optimized oral therapy.
Clinical Trials Related to Apokyn (Apomorphine)
Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment [Active, not recruiting]
The purposes of the study are to determine:
i. The rate of Apokyn®-related nausea and vomiting in subjects treated with oral Tigan®
compared to those treated with oral placebo (inactive substance).
ii. The need for continued use of Tigan® for control of nausea and vomiting with on-going
Apokyn® treatment for up to 12 weeks
iii. Possible side effects of Tigan® when used in combination with Apokyn® in subjects with
Parkinson's Disease
iv. If Tigan® slows or hastens the body's metabolism (clearance) of Apokyn®.
Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease [Not yet recruiting]
The purpose of this study is to compare the effects of apomorphine, given by two different
methods, to determine how best to manage dyskinesias.
Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease [Completed]
Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO) [Recruiting]
OH dependence is associated with DA receptor changes. Both, the apomorphine test and the
D2Rec SPECt are usefull for monitoring DA receptor status. We aimed at studying whether DA
receptor hypofunction, assessed by means of the apomorphine test and the D2Rec SPECT, is a
marker of relapse in detoxified OH dependents patients.
Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study [Completed]
Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations.
We suppose that painful symptoms could be related to the neurotransmitter deficit of PD. So,
we would like to evaluate the involvement of dopaminergic system in nociceptive processing in
PD patients. The objectives of this study is to assess and to compare the effect of a
dopamine agonist administration on the nociceptive threshold and on the cerebral activity
using positrons emission tomography (PET scan) in two groups of PD patients (in 16 painful PD
patients and in 16 pain free PD patients). We hypothesise that dopamine agonist could
normalise nociceptive threshold and cerebral activity which were both abnormal in PD
patients. Moreover, we think that painful PD patients could be more improved by dopamine
agonist than pain free PD patients.
|
